21
May
2020
A Glimmer of Hope, and a Premature Celebration
We all woke up Monday morning and saw an encouraging headline. Then things started to go downhill. To recap, Moderna, the Cambridge, Mass.-based messenger RNA therapeutics and vaccines company, provided a snapshot of preliminary data from its Phase I trial of a SARS-CoV-2 vaccine candidate, being tested in collaboration with Tony Fauci’s crew at the National Institute of Allergy and... Read More
21
May
2020
Creating Leaner and Meaner Clinical Trials for the Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
May
2020
Day One, Taking a Page from Rare Disease Playbook, Raises $60M for Kids With Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.